GlassScriptPhysician profile
Robert Anthony Yap
NPI 1154651933
$3,895.72
in general payments reported to CMS, 2019-2025
28 companies · $1,183 in 2025
The $1,183 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $206 · 2022: $464 · 2023: $994 · 2024: $1,049 · 2025: $1,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,116 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,115.94 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,030.78 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $333.23 | 2021-2024 | Spravato, Xarelto |
| Glaxosmithkline, LLC. | $248.10 | 2024-2025 | Arexvy, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $242.33 | 2025 | Austedo Xr |
| Indivior INC. | $200.18 | 2021-2025 | Sublocade |
| Astrazeneca Pharmaceuticals LP | $192.06 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $186.86 | 2023-2024 | Wegovy |
| Amgen INC. | $151.56 | 2022-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $144.21 | 2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $136.31 | 2023-2025 | Cologuard Collection Kit |
| Seqirus USA INC | $126.93 | 2022-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Kowa Pharmaceuticals America, INC. | $98.27 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.91 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $80.69 | 2023-2024 | Rexulti, Abilify Maintena |
| Biohaven Pharmaceutical Holding Company LTD. | $75.92 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $72.24 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $67.80 | 2024 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.43 | 2024-2025 | Xifaxan, Trulance |
| Mayne Pharma Commercial LLC | $64.50 | 2023-2024 | |
| Lundbeck LLC | $62.86 | 2024-2025 | Rexulti |
| Braeburn INC. | $46.71 | 2025 | Brixadi |
| Biohaven Pharmaceuticals, INC. | $43.52 | 2021 | |
| Merck Sharp & Dohme LLC | $32.88 | 2021 | |
| Nevro Corp. | $26.19 | 2023 | Senza |
| Genentech USA, INC. | $25.46 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $22.13 | 2025 | Gvoke Hypopen |
| Amarin Pharma, INC. | $17.52 | 2021 | |
| Medicomp INC | $15.14 | 2023 | Telepatch Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Yap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.